Neural networks in the prediction of survival in patients with colorectal cancer. by Grumett, S, Snow, P, Kerr, D

The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy. by Grumett, SA, Archer, V, Midgley, R, Mulholland, P, Nicum, S, Blewitt, L, Kerr, D

QUASAR Collaborative Group: a randomised study of adjuvant chemotherapy (CT) vs observation in predominantly stage II colorectal cancer by Kerr, D, Barnwell, J, Hills, R, McConkey, C, Williams, N, Quirke, P, Grumett, S, Gray, R

CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL by Midgley, R, Love, S, Potter, V, Segelov, E, Ferry, DR, Weaver, A, Scudder, C, Julier, P, Grumett, S, Kerr, D

Monitoring advances including consent: learning from COVID-19 trials and other trials running in UKCRC registered clinical trials units during the pandemic by Sharon B. Love, Emma Armstrong, Carrie Bayliss, Melanie Boulter, Lisa Fox, Joanne Grumett, Patricia Rafferty, Barbara Temesi, Krista Wills, Andrea Corkhill

Get full text

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. by Midgley, R, McConkey, C, Johnstone, E, Dunn, J, Smith, J, Grumett, SA, Julier, P, Iveson, C, Yanagisawa, Y, Warren, B, Langman, M, Kerr, D

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients by S Ahmad, S, Qian, W, Ellis, S, Mason, E, Khattak, M, Gupta, A, Shaw, H, Quinton, A, Kovarikova, J, Thillai, K, Rao, A, Board, R, Nobes, J, Dalgleish, A, Grumett, S, Maraveyas, A, Danson, S, Talbot, T, Harries, M, Marples, M, Plummer, R, Kumar, S, Nathan, P, Middleton, M, Larkin, J, Lorigan, P, Wheater, M, Ottensmeier, C, Corrie, P

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP) by Starkey, T, Ionescu, MC, Tilby, M, Little, M, Burke, E, Fittall, MW, Khan, S, Liu, JKH, Platt, JR, Mew, R, Tripathy, AR, Watts, I, Williams, ST, Appanna, N, Al-Hajji, Y, Barnard, M, Benny, L, Burnett, A, Bytyci, J, Cattell, EL, Cheng, V, Clark, JJ, Eastlake, L, Gerrand, K, Ghafoor, Q, Grumett, S, Harper-Wynne, C, Kahn, R, Lee, AJX, Lomas, O, Lydon, A, Mckenzie, H, Panneerselvam, H, Pascoe, JS, Patel, G, Patel, V, Potter, VA, Randle, A, Rigg, AS, Robinson, TM, Roylance, R, Roques, TW, Rozmanowski, S, Roux, RL, Shah, K, Sheehan, R, Sintler, M, Swarup, S, Taylor, H, Tillett, T, Tuthill, M, Williams, S, Ying, Y, Beggs, A, Iveson, T, Lee, SM, Middleton, G, Middleton, M, Protheroe, A, Fowler, T, Johnson, P, Lee, LYW

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP) by Thomas Starkey, Maria C. Ionescu, Michael Tilby, Martin Little, Emma Burke, Matthew W. Fittall, Sam Khan, Justin K. H. Liu, James R. Platt, Rosie Mew, Arvind R. Tripathy, Isabella Watts, Sophie Therese Williams, Nathan Appanna, Youssra Al-Hajji, Matthew Barnard, Liza Benny, Alexander Burnett, Jola Bytyci, Emma L. Cattell, Vinton Cheng, James J. Clark, Leonie Eastlake, Kate Gerrand, Qamar Ghafoor, Simon Grumett, Catherine Harper-Wynne, Rachel Kahn, Alvin J. X. Lee, Oliver Lomas, Anna Lydon, Hayley Mckenzie, NCRI Consumer Forum, Hari Panneerselvam, Jennifer S. Pascoe, Grisma Patel, Vijay Patel, Vanessa A. Potter, Amelia Randle, Anne S. Rigg, Tim M. Robinson, Rebecca Roylance, Tom W. Roques, Stefan Rozmanowski, René L. Roux, Ketan Shah, Remarez Sheehan, Martin Sintler, Sanskriti Swarup, Harriet Taylor, Tania Tillett, Mark Tuthill, Sarah Williams, Yuxin Ying, Andrew Beggs, Tim Iveson, Siow Ming Lee, Gary Middleton, Mark Middleton, Andrew Protheroe, Tom Fowler, Peter Johnson, Lennard Y. W. Lee

Get full text